摘要
目的:研究131I抗VEGF单克隆抗体(Sc7269)在荷人骨肉瘤裸鼠体内生物分布,探讨131I Sc7269用于骨肉瘤放射免疫治疗的可行性,并比较系统给药与局部给药在生物学分布上的差异。方法:Iodogen法131I标记Sc7269。24只荷人骨肉瘤裸鼠各12只分别瘤内注射和静脉注射131I Sc7269,进行生物分布研究。结果:2种给药方式中,131I Sc7269均可在肿瘤组织内特异性聚集。局部给药后肿瘤组织的放射性摄取在各个时间点明显高于系统给药,而其他组织的放射性摄取明显低于系统给药组。结论:131I Sc7269具有靶向骨肉瘤的特性,且局部给药较系统给药在体内生物学分布上具有明显优越性。
Objective:To explore the feasibility of radioimmunotherapy of human bone sarcoma xenograft with (131)I anti VEGF monoclonal antibody (Sc-7269) through studying the biodistribution of (131)I-Sc-7269 in human bone sarcoma xenograft and to compare the difference of system administration and local administration.Methods:Sc-7269 was labeled with (131)I by the Iodogen method.24 nude mice bearing human bone sarcoma xenografts were used for the biodistribution study after intratumoral injection (n=12) or intravenous injection (n=12) of (131)I-Sc-7269.Results: (131)I-Sc-7269 could selectively aggregate in tumor,whatever approach was used.And compared with systemic administration,local administration of (131)I-Sc-7269 produced prolonged higher tumor radioactivity with lesser normal tissue uptake.Conclusion: (131)I-Sc-7269 has a considerable targeting activity,and local administration is preferable in biodistribution.
出处
《放射学实践》
2005年第6期539-541,共3页
Radiologic Practice
关键词
骨肉瘤
放射免疫疗法
抗体
单克隆
生物学
Osteosarcoma
Radioimmunotherapy
Antibodies,monoclonal
Biology
